Price Negotiation And Sickle Cell ‘Cures’: Dueling Biopharma Headlines This Fall
Executive Summary
The two sides of the US public’s perceptions of the biopharma industry are likely to dominate the headlines this fall. Will the industry emerge defined by innovation and hope for better health? Or by massive profits protected by litigation?